| Safety of regadenoson in patients with end-stage renal disease. | |
| | |
MedLine Citation:
|
PMID: 20102905 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Regadenoson is a selective A(2A) receptor agonist that was recently approved by the Food and Drug Administration for vasodilator stress myocardial perfusion imaging. Because the drug is cleared by renal excretion, its safety in patients with end-stage renal disease (ESRD) needs to be determined. We studied 277 consecutive patients with ESRD who had undergone regadenoson stress gated single photon emission computed tomography myocardial perfusion imaging and compared their side effect profile and safety outcome to those of 134 patients with normal kidney function. The ESRD group included 164 men (59%) and the control group included 73 men (54%; p = NS). The patients with ESRD were younger than the controls (52 +/- 11 years vs 61 +/- 12 years; p <0.001). The myocardial perfusion imaging findings were abnormal in 53 patients (19%) with ESRD and in 24 patients in the control group (18%; p = NS). The left ventricular ejection fraction was 57 +/- 12% in the ESRD group and 64 +/- 12% in the control group (p <0.001). The changes in heart rate and systolic blood pressure (from baseline to peak stress) were 20 +/- 12 beats/min versus 22 +/- 13 beats/min and -11 +/- 24 mm Hg versus -12 +/- 23 mm Hg in the ESRD and control groups, respectively (p = NS for both). Very few patients in either group reported symptoms during the stress test. No medication-related hospitalizations, serious events, or death occurred in either group within 30 days of the study. In conclusion, this is the first study to document the safety of regadenoson in a large number of patients with ESRD. The drug was well tolerated, and the hemodynamic and side effect profiles were similar to those of patients with normal renal function. |
| | |
Authors:
|
Wael Aljaroudi; Daniel Hermann; Fadi Hage; Jaekyeong Heo; Ami E Iskandrian |
Related Documents
:
|
6481015 - Functional assessment of the fontan operation: combined m-mode, two-dimensional and dop... 704515 - Prognosis and possible presymptomatic manifestations of congestive cardiomyopathy (cocm). 2744805 - Systolic time intervals in dilated cardiomyopathy. 12177655 - Echocardiography-derived variables predict outcome in patients with nonischemic dilated... 12930375 - T cell receptor vb repertoire diversity in patients with immune thrombocytopenia follow... 10799825 - Emergency surgery of acute traumatic arteriovenous fistulas. |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2009-11-18 |
Journal Detail:
|
Title: The American journal of cardiology Volume: 105 ISSN: 1879-1913 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2010 Jan |
Date Detail:
|
Created Date: 2010-01-27 Completed Date: 2010-03-04 Revised Date: 2010-04-12 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 133-5 Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiovascular Disease, University of Alabama, Birmingham, Alabama, USA. waljaroudi@cardmail.dom.uab.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Exercise Test
/
methods Female Follow-Up Studies Heart Diseases / complications, physiopathology, radionuclide imaging* Humans Kidney Failure, Chronic / complications*, physiopathology Male Middle Aged Prognosis Purines / administration & dosage, diagnostic use* Pyrazoles / administration & dosage, diagnostic use* Reproducibility of Results Stroke Volume / physiology Tomography, Emission-Computed, Single-Photon / methods* Ventricular Function, Left / physiology |
| Chemical | |
Reg. No./Substance:
|
0/Purines; 0/Pyrazoles; 0/regadenoson |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relation of the Ankle Brachial Index to Left Ventricular Ejection Fraction.
Next Document: Homicide by fright: the intersection of cardiology and criminal law.